

CONTENTS

This document is issued by Genuine Biotech Limited solely in connection with the [REDACTED] and does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the [REDACTED] offered by this document pursuant to the [REDACTED]. This document may not be used for the purpose of, and does not constitute, an offer or invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED] or the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document and the [REDACTED] of the [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely only on the information contained in this document to make your investment decision. Our Company has not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not made in this document must not be relied on as having been authorized by our Company, the Sole Sponsor, [REDACTED], any of its or their respective directors, officers, representatives, employees, agents or professional advisors or any other person or party involved in the [REDACTED].

	<i>Page</i>
EXPECTED TIMETABLE	i
CONTENTS	iv
SUMMARY	1
DEFINITIONS AND ACRONYMS	17
GLOSSARY OF TECHNICAL TERMS	29
FORWARD-LOOKING STATEMENTS	35
RISK FACTORS	36
WAIVER FROM STRICT COMPLIANCE WITH THE REQUIREMENTS UNDER THE LISTING RULES AND EXEMPTION FROM THE COMPANIES (WINDING UP AND MISCELLANEOUS PROVISIONS) ORDINANCE	71
INFORMATION ABOUT THIS DOCUMENT AND THE [REDACTED]	74
DIRECTORS AND PARTIES INVOLVED IN THE [REDACTED]	77
CORPORATE INFORMATION	80
INDUSTRY OVERVIEW	82
REGULATORY OVERVIEW	98
HISTORY, REORGANIZATION AND CORPORATE STRUCTURE	111
BUSINESS	135

CONTENTS

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS	221
DIRECTORS AND SENIOR MANAGEMENT.	225
SUBSTANTIAL SHAREHOLDERS	239
SHARE CAPITAL	241
FINANCIAL INFORMATION	243
FUTURE PLANS AND [REDACTED]	269
[REDACTED]	272
STRUCTURE OF THE [REDACTED].	281
HOW TO APPLY FOR [REDACTED].	289
APPENDIX I – ACCOUNTANTS’ REPORT	I-1
APPENDIX II – UNAUDITED [REDACTED] FINANCIAL INFORMATION	II-1
APPENDIX III – SUMMARY OF THE CONSTITUTION OF THE COMPANY AND CAYMAN ISLANDS COMPANY LAW	III-1
APPENDIX IV – STATUTORY AND GENERAL INFORMATION	IV-1
APPENDIX V – DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES AND DOCUMENTS ON DISPLAY	V-1